NCT00048100

Anti-Leukemic Dendritic Cell Activated Donor Lymphocytes

Anti-Leukemic Dendritic Cell Activated Donor Lymphocytes for Therapy of Relapsed Leukemia After Allogeneic Stem Cell Therapy

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 2 (actual)
• Sponsor: M.D. Anderson Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Objectives: 1. Determine the toxicity of infusions of allogeneic donor lymphocytes activated by acute leukemia derived dendritic cells (DC/ADL) in relapsed patients after allo-stem cell transplants. 2. Quantitate the alloreactivity of DC/ADL and circulating immune effector cells in patients after infusion. 3. Assess efficacy of acute myelogenous leukemia (AML) or Chronic Myelogenous Leukemia in Blastic Crisis (CML-BC) derived dendritic cells and activated lymphocytes in promoting and sustaining remission in patients with relapse after allo-BMT or stem cell transplant.

Conditions

• Leukemia, Myelocytic, Acute

Interventions

Type	Name	Description
PROCEDURE	Apheresis	Apheresis for T-Cell collection
BIOLOGICAL	Stem Cell Transplant	Stem cell or marrow infusions of allogeneic donor lymphocytes activated by acute leukemia derived dendritic cells (DC/ADL).

Timeline

• Start date: 2001-02-01
• Primary completion: 2005-05-01
• Completion: 2005-05-01
• First posted: 2002-10-25
• Last updated: 2018-10-31

Locations

1 site across 1 country: United States